Compare CMPX & BTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CMPX | BTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 752.4M | 773.8M |
| IPO Year | N/A | N/A |
| Metric | CMPX | BTX |
|---|---|---|
| Price | $5.53 | $6.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $13.44 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 938.4K |
| Earning Date | 11-05-2025 | 11-01-2025 |
| Dividend Yield | N/A | ★ 13.82% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $5.10 |
| 52 Week High | $5.86 | $8.31 |
| Indicator | CMPX | BTX |
|---|---|---|
| Relative Strength Index (RSI) | 67.47 | 52.33 |
| Support Level | $5.13 | $6.66 |
| Resistance Level | $5.86 | $6.90 |
| Average True Range (ATR) | 0.32 | 0.17 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 72.12 | 82.30 |
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
BlackRock Technology and Private Equity Term Trust objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation. The Trust will invest in equity securities issued by mid - and small capitalization companies that the Trust's adviser believes have above-average earnings growth potential.